Search results
6 cze 2023 · This article reviews the history of memantine, the mechanism, and limitations of memantine for AD, and memantine and combination therapy, and compares memantine with other drugs approved by the FDA for the treatment of AD.
2 mar 2007 · Memantine is well absorbed from the gastrointestinal tract after oral administration, and its absorption is unaffected by food (Forest Laboratories 2003). It reaches a maximum plasma concentration (Cmax) after a single dose in 3–7 hours, and it has a plasma half-life of about 60–80 hours.
13 mar 2018 · The data in preclinical studies suggests that MEM has a positive impact on improving AD brain neuropathology, as well as in preventing Aβ production, aggregation, or downstream neurotoxic consequences, in part through the blockade of extrasynaptic NMDAR.
14 wrz 2020 · Memantine preferentially binds to NMDARs and prevents the influx of calcium ions, thereby preventing the disruption of synaptic plasticity. The onset of action is after 3 to 7 hours with a half-life of 60 to 80 hours; it is metabolized in the liver and excreted through the kidneys.
2 wrz 2010 · The small peak-to-trough steady-state variation with 10 mg twice- and 20 mg once-daily dosing schemes could be anticipated because of the inherently long half-life of elimination of 60 to 80 hours in subjects with normal renal function.
2 wrz 2010 · RESULTS. In memantine‐naive subjects, the initiation of 20 mg once daily is predicted to result in an initial peak plasma concentration of 19.5 μg/L, twice that which would occur after an initial dose of 10 mg, 5 hours after ingestion. Because the elimination half‐life of memantine is approximately 70 hours, steady state is reached after 2 weeks.
5 lis 2022 · The N-methyl-D-Aspartate receptor antagonist memantine with its less popular monoamine reuptake-inhibiting properties provides beneficial effects in patients with advanced Alzheimer’s disease on an acetylcholine esterase inhibitor treatment regimen.
